8-K filed Aug 11, 2026 at 06:47 ET
Cardinal Health reported strong Q4 FY2026 results with revenue of $63.7B (+6% YoY) and GAAP EPS of $1.70 (+70% YoY). Non-GAAP EPS of $2.91 (+40% YoY) included a $0.31 one-time benefit from IEEPA tariff refunds; excluding that, non-GAAP EPS grew 25% to $2.60. The company provided FY2027 non-GAAP EPS guidance of $12.40-$12.60 (+13-15% growth), above its long-term target, and announced a $5.0B incremental share repurchase authorization. The combination of a strong Q4 beat, raised FY2027 guidance above consensus, and a massive capital return program is a clear bullish signal for the stock.